Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study
Authors' conclusion
The REALISED study provides the first real-world evidence of the use of oral semaglutide in Thai patients with T2D, demonstrating significant improvements in glycaemic control and weight reduction across routine care settings.
Study context
- Population
- Thai patients with T2D initiating oral semaglutide between April 2022 and December 2023, no prior injectable therapy, ≥26 weeks of treatment
- Participants
- 195 patients
- Outcome
- Change in HbA1c from baseline to end-of-study
- Follow-up
- Week 26
Methodological detailsmulti-centre, real-world, Oral semaglutide used predominantly as add-on therapy (190/195 [97.4%])
- Multi-centre
- Real-world
- Oral semaglutide used predominantly as add-on therapy (190/195 [97.4%])
Main finding
As reported in the abstract
Change in HbA1c from baseline · EoS (Week 26)
Mean HbA1c change
−0.7%
95% CI −0.9 to −0.5p < 0.0001
Observational data: associations, not effects.
Secondary outcomes
Change in body weight
- Mean body weight change
- −4.3 kg (95% CI: −5.5 to −3.2; p < 0.0001)
HbA1c < 7% · end-of-study (EoS)
- Achieved HbA1c < 7%
- 75.9% (117/154)
Composite: HbA1c < 7% with ≥ 3% weight loss · EoS
- Met composite endpoint
- 57.7% (71/123)
- Post hoc
Dose escalation from 3 mg to 14 mg
- By Week 26
- 53.2%
- By Week 52
- 70.4%
Safety
- No severe hypoglycaemia occurred
Original publication
Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Type 2 Diabetes: Real‐World Evidence From the REALISED Study. Diabetes Obes Metab. Published 24 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →